SOUTH SAN FRANCISCO, Calif. (AP) _ CytomX Therapeutics Inc. (CTMX) on Thursday reported a loss of $23.7 million in its third quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 52 cents.
The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.
The biopharmaceutical company posted revenue of $10.7 million in the period, which also fell short of Street forecasts. Three analysts surveyed by Zacks expected $23.6 million.
CytomX Therapeutics shares have decreased 59% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $6.15, a decrease of 61% in the last 12 months.